Nasus Pharma Ltd. (NSRX)
NYSEAMERICAN: NSRX · Real-Time Price · USD
2.910
-0.270 (-8.49%)
At close: Apr 28, 2026, 4:00 PM EDT
2.880
-0.030 (-1.03%)
After-hours: Apr 28, 2026, 8:00 PM EDT
Company Description
Nasus Pharma Ltd., a clinical-stage specialty pharmaceutical company focused on the development of intranasal drugs to treat emergency medical conditions.
It offers Powder-Based Intranasal (PBI) products to address acute medical conditions and public health threats.
The company’s products include NS002, Intranasal Epinephrine for assisting in severe allergic reaction emergency situations and NS001, an Intranasal Naloxone powder nasal spray for the treatment of opioid overdose.
Nasus Pharma Ltd. was incorporated in 2019 and is based in Tel Aviv-Yafo, Israel.
Nasus Pharma Ltd.
| Country | Israel |
| Founded | 2019 |
| IPO Date | Aug 14, 2025 |
| Industry | Drug Manufacturers - General |
| Sector | Healthcare |
| Employees | 7 |
| CEO | Dan Teleman |
Contact Details
Address: Yigal Alon 65 Tel Aviv-Yafo, 6744317 Israel | |
| Phone | 972 3 573 6632 |
| Website | nasuspharma.com |
Stock Details
| Ticker Symbol | NSRX |
| Exchange | NYSEAMERICAN |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $8.00 |
| CIK Code | 0002029039 |
| CUSIP Number | 001218155 |
| ISIN Number | IL0012181553 |
| Employer ID | 51-6022712 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dan Teleman MBA M.Sc. | Chief Executive Officer and Director |
| Ehud Moshe Gilboa MBA | Co-Founder and Executive Chairman |
| Dr. Dalia Megiddo M.B.A., M.D., Ph.D. | Co-Founder, Director, Chief Medical Officer and Chief Development Officer? |
| Eyal Rubin M.B.A. | Chief Financial Officer and Executive Vice President |
| Yifat Bar | Vice President of Administration and Human Resources |
| Dr. Galia Temtsin Kryaz Ph.D. | Director of CMC and Product Development |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 7, 2026 | SCHEDULE 13G | Filing |
| Mar 31, 2026 | EFFECT | Notice of Effectiveness |
| Mar 27, 2026 | POS AM | Post-Effective amendments for registration statement |
| Mar 25, 2026 | 6-K | Report of foreign issuer |
| Mar 25, 2026 | 20-F | Annual and transition report of foreign private issuers |
| Mar 16, 2026 | 6-K | Report of foreign issuer |
| Mar 13, 2026 | EFFECT | Notice of Effectiveness |
| Mar 6, 2026 | 6-K | Report of foreign issuer |
| Mar 4, 2026 | 6-K | Report of foreign issuer |
| Mar 2, 2026 | F-1 | Registration statement for certain foreign private issuers |